PERHAPS A GIFT VOUCHER FOR MUM?: MOTHER'S DAY

Close Notification

Your cart does not contain any items

Atlas of Rheumatoid Arthritis

Paul Emery

$152.95   $122.40

Paperback

Not in-store but you can order this
How long will it take?

QTY:

English
Springer Healthcare
29 June 2015
Atlas of Rheumatoid Arthritis is a high-quality educational initiative, written by leaders in the field of rheumatology, containing a collection of approximately 150 relevant images, with extended descriptive captions and a comprehensive bibliography. The Atlas of Rheumatoid Arthritis will provide clinicians with a visual guide to rheumatoid arthritis, focusing on assessment, diagnosis and treatment, including newer research into the signalling pathways involved in the pathogenesis of RA, before focusing on the treatment of RA. Rheumatoid arthritis (RA) is the most common and most serious of the inflammatory arthritic disorders, and it dominates clinical rheumatological practice. Effective, early treatment is vital as this can slow the course of the disease and reduce joint damage. RA is usually treated using disease-modifying anti-rheumatic drugs (DMARDs), most commonly methotrexate. The newest treatments target the disease-causing immune elements specifically and directly.

Edited by:  
Imprint:   Springer Healthcare
Country of Publication:   United Kingdom
Edition:   2015 ed.
Dimensions:   Height: 210mm,  Width: 148mm,  Spine: 15mm
Weight:   495g
ISBN:   9781907673900
ISBN 10:   1907673903
Pages:   264
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Paperback
Publisher's Status:   Active
1. Classification of rheumatoid arthritis 2. Pre-rheumatoid arthritis What is pre-rheumatoid arthritis? Risk factors for rheumatoid arthritis Systemic autoimmunity associated with rheumatoid arthritis Symptoms without clinical arthritis Unclassified arthritis 3. Early rheumatoid arthritis Introduction Pathology in early rheumatoid arthritis Diagnosis of early rheumatoid arthritis Classification of rheumatoid arthritis Management of early rheumatoid arthritis Recommendations for the management of early rheumatoid arthritis 4. Established rheumatoid arthritis Introduction Stages of established rheumatoid arthritis Common clinical presentations Introduction Stages of established rheumatoid arthritis Common clinical presentations 5. Remission and rheumatoid arthritis Introduction Defining remission Imaging remission Immune-mediated remission Drug-free remission Optimal dose reduction regimes for patients in remission Part TWO Imaging of Rheumatoid Arthritis 6. Magnetic resonance imaging in rheumatoid arthritis Introduction Technical aspects Visualizing rheumatoid arthritis Diagnosing rheumatoid arthritis Monitoring disease activity and structural damage 7. Ultrasound imaging in rheumatoid arthritis 7. Ultrasound imaging in rheumatoid arthritis Introduction Ultrasound and rheumatoid arthritis Cartilage damage Management of rheumatoid arthritis with ultrasound: diagnosis, therapeutic follow-up, remission, and flare Conclusion 8. Dual energy X-ray absorptiometry in rheumatoid arthritis Introduction Bone remodeling in rheumatoid arthritis Bone damage imaging in rheumatoid arthritis Treatment of bone loss in rheumatoid arthritis Part three Treatment of rheumatoid arthritis 9. Methotrexate Introduction Historical perspective Mechanism of action and pharmacokinetics Dosing Benefits Monitoring 10. Immunotherapy Introduction Nonbiologic disease-modifying antirheumatic drugs Biologic disease-modifying antirheumatic drugs Cost-effectiveness of immunotherapy in early rheumatoid arthritis Recommendations for the use of disease-modifying antirheumatic drug therapies Safety of immunotherapy Prospective new targets for immunotherapy 11. Rituximab B-cell development and differentiation Efficacy of rituximab in rheumatoid arthritis 12. Novel therapies in rheumatoid arthritis: small moleculesIntroduction Inhibiting intracellular signaling pathways Conclusion

Professor Paul Emery is the Arthritis Research UK Professor of Rheumatology and Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the Leeds Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, United Kingdom. Professor Emery was the President of the European League Against Rheumatism (EULAR) from 2009–2011 and has served on the editorial boards major rheumatology journals including Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinical and Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President of International Extremity MRI Society (ISEMIR) and is a National Institute for Health Research (NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award for Clinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULAR Prize for outstanding contribution to rheumatology research; and the Carol Nachman Prize for outstanding rheumatology research. Professor Emery’s research interests center around the immunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connective tissue diseases. He has a special interest in the factors leading to persistent inflammation and has published over 950 peer-reviewed articles in this area. is the Arthritis Research UK Professor of Rheumatology and Director ofthe Leeds Institute of Rheumatic and Musculoskeletal Medicine and the Director of the Leeds Musculoskeletal Biomedical Research Unit at Leeds Teaching Hospitals Trust in Leeds, United Kingdom. Professor Emery was the President of the European League Against Rheumatism (EULAR) from 2009–2011 and has served on the editorial boards major rheumatology journals including Rheumatology, Arthritis and Rheumatism, Annals of the Rheumatic Diseases, Clinical and Experimental Rheumatology, and Clinical Rheumatology. He was the inaugural President of International Extremity MRI Society (ISEMIR) and is a National Institute for Health Research (NIHR) Senior Investigator. Professor Emery is a recipient of the Roche Biennial Award for Clinical Rheumatology; the Rheumatology Hospital Doctor of the Year Award; the EULAR Prize for outstanding contribution to rheumatology research; and the Carol Nachman Prize for outstanding rheumatology research. Professor Emery’s research interests center around the immunopathogenesis and immunotherapy of rheumatoid arthritis, spondyloarthritis, and connective tissue diseases. He has a special interest in the factors leading to persistent inflammation and has published over 950 peer-reviewed articles in this area.

See Also